TRIPLE-NEGATIVE BREAST CARCINOMA

This study tests a DNA-based vaccine called STEMVAC in 33 people with early-stage triple negative breast cancer (stages IB to III). The vaccine targets proteins found on breast cancer stem cells and aims to train the immune system to recognize and attack these cells. The main goa…

This study tested whether adding trastuzumab to standard chemotherapy before surgery helps shrink breast tumors more effectively. About 92 women with early-stage breast cancer (some HER2-positive, some HER2-negative) took part. The goal was to see if the combination reduces the a…

This study tests whether combining the immunotherapy drug avelumab with other medications can help people with advanced triple-negative breast cancer. About 145 adults with stage IV or inoperable breast cancer will receive one of several drug combinations. The goal is to see if t…

This early-phase trial tested the safety and best dose of combining veliparib with the chemotherapy drug carboplatin in 44 people with HER2-negative breast cancer that had spread. The goal was to see if veliparib could stop cancer cells from repairing damage caused by carboplatin…

This early-phase trial studies two drug combinations (olaparib plus vistusertib or olaparib plus capivasertib) in people with recurrent endometrial, triple-negative breast, ovarian, or related cancers. The main goal is to find the safest dose and understand side effects. About 15…

This early-phase study tests a new drug called BAY 1895344 combined with standard chemotherapy (cisplatin, with or without gemcitabine) in people with advanced solid tumors, especially bladder cancer. The main goals are to find the safest dose and understand side effects. About 7…

This early-stage study tests a new cancer vaccine (p53MVA) combined with the immunotherapy drug pembrolizumab in people with advanced solid tumors that have not responded to other treatments. The vaccine helps the immune system recognize and attack cancer cells, while pembrolizum…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy before surgery helps shrink tumors more effectively in people with stage II-III triple negative breast cancer. About 67 participants will receive either chemo alone or chemo plus atezoliz…

This study tests whether combining two drugs—cediranib (which cuts off a tumor's blood supply) and olaparib (which stops cancer cells from repairing themselves)—works better than olaparib alone for people whose ovarian, fallopian tube, peritoneal, or triple-negative breast cancer…

This study tests whether platinum-based chemotherapy (cisplatin or carboplatin) works better than capecitabine in people with a certain type of triple-negative breast cancer that still remains after initial chemotherapy and surgery. About 415 participants with stage II or III bre…

This study tests whether giving two immunotherapy drugs (decitabine and pembrolizumab) before standard chemotherapy can boost the body's immune attack on HER2-negative breast cancer. About 46 adults with locally advanced disease will receive this short course, then proceed to usu…

This early-phase trial tests the safety and best dose of two oral drugs, ZEN003694 and binimetinib, taken together. It is for people with advanced solid tumors that have RAS pathway changes or triple-negative breast cancer that has spread or cannot be removed by surgery. The stud…

This early-phase study tests a drug called berzosertib combined with radiation therapy for people with certain types of breast cancer that no longer respond to chemotherapy. The goal is to find the safest dose and see if the combination can shrink or stabilize tumors better than …

This study tests a drug called pembrolizumab in people with advanced inflammatory breast cancer or triple-negative breast cancer that has spread. Participants had already responded to or stabilized with chemotherapy. The drug helps the immune system attack cancer cells, and the g…

This phase 3 trial tests whether adding the immunotherapy drug pembrolizumab after standard chemotherapy helps prevent triple-negative breast cancer from returning. About 1,155 patients with residual cancer after chemo are randomly assigned to receive pembrolizumab or a placebo. …

This study tests a combination of two drugs, cediranib and olaparib, in people with advanced or inoperable solid tumors, including certain breast, lung, and pancreatic cancers. The goal is to see if the combo can shrink tumors or slow their growth by blocking enzymes that cancer …

This study compares two different chemotherapy combinations given before surgery for a fast-growing, hard-to-treat type of breast cancer called triple-negative inflammatory breast cancer. Researchers want to see if adding a targeted drug called panitumumab to standard chemotherap…

This study looks at whether watching an online genetics video, with or without phone counseling, can reduce the stress women feel about their cancer risk. It involves 5,200 women aged 30 or older who have had triple-negative breast cancer and still have at least one ovary. Resear…

This study looks at a blood test that finds tiny bits of tumor DNA in the blood of people with early-stage breast cancer. The goal is to see if this test can tell who still has cancer cells after treatment and might need more therapy. About 350 adults with stage I-III breast canc…

This study collects tissue and blood samples, along with medical information, from 1,600 people with various advanced cancers. The goal is to track how cancer changes over time and during treatment. Researchers hope this will help them understand why some cancers resist therapy a…

This study was designed to see if an online mental health program could help women with advanced gynecologic or breast cancer cope with the fear of their cancer coming back. It planned to compare the program to standard educational materials. However, the study was withdrawn befo…

This study looks at whether advanced breast imaging scans can predict how well chemotherapy is working in people with triple negative breast cancer. About 96 participants will get special MRI and molecular breast imaging scans before, during, and after chemo. The goal is to see i…